235 filings
Page 2 of 12
F-1/A
daj3g lbw
13 Jul 23
Registration statement (foreign) (amended)
5:08pm
CORRESP
1rkufs2h
12 Jul 23
Correspondence with SEC
12:00am
F-1/A
luj27 wji
12 Jul 23
Registration statement (foreign) (amended)
12:00am
CORRESP
elg u91i5
12 Jul 23
Correspondence with SEC
12:00am
6-K
f9nbg
10 Jul 23
Current report (foreign)
8:10am
FWP
wuz96sh
28 Jun 23
Free writing prospectus
8:40am
F-1/A
n7ezqd40
28 Jun 23
Registration statement (foreign) (amended)
8:37am
F-1
5tblvfwrq
16 Jun 23
Registration statement (foreign)
4:15pm
6-K
do1g e403ym
1 Jun 23
Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results
8:14am
6-K
3osfdm9
12 May 23
Current report (foreign)
7:00am
6-K
vkvvhn1i15yn9ysdg
11 May 23
Current report (foreign)
4:15pm
6-K
8a2tosdpoo8hc
9 May 23
Current report (foreign)
7:14am
6-K
fbrnm y9e3zcwi
4 May 23
Current report (foreign)
4:15pm
6-K
0wa0tt
4 May 23
Galmed Pharmaceuticals forms a Strategic Partnership
4:14pm
6-K
c9ftq7i
30 Mar 23
Current report (foreign)
4:27pm
6-K
wqc58
8 Feb 23
Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt
8:15am
6-K
u2a zhyvz
5 Jan 23
Current report (foreign)
4:30pm
6-K
cip b4owt
4 Jan 23
Galmed reports results from the Open-Label part of the ARMOR study showing improvements in histology, imaging, and biomarkers with Aramchol
8:11am
6-K
k0z5jriem6 jl36l
14 Dec 22
Current report (foreign)
5:08pm